Artificial pancreas: Fuzzy logic and control of glycemia

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 21, Issue 4, 2014, Pages 251-256

  Nimri, Revital ^a   Phillip, Moshe ^a,b  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

artificial pancreas; closed loop; low glucose suspend; MD Logic AP; overnight glucose control; type 1 diabetes

Indexed keywords

GLUCOSE; INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ARTIFICIAL PANCREAS; BLOOD GLUCOSE MONITORING; DRUG DELIVERY SYSTEM; FUZZY LOGIC; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN PUMP; NOCTURNAL HYPOGLYCEMIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; HYPOGLYCEMIA; INSULIN INFUSION; METABOLISM; TIME;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FUZZY LOGIC; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; PANCREAS, ARTIFICIAL; TIME FACTORS;

EID: 84903817961     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000073     Document Type: Review

References (45)

1. Pickup JC. Insulin-pump therapy for type 1 diabetes mellitus. N Engl J Med 2012; 366:1616-1624.
2. Phillip M, Danne T, Shalitin S, et al. Use of continuous glucose monitoring in children and adolescents. Pediatr Diabetes 2012; 13:215-2283.
3. HB M. Findings from the Hvidre Study Group on Childhood Diabetes: metabolic control and quality of life. In: Diabetes HSGoC, ed. Vol 57: Horm Res; 2002; 117-120.
4. RW B. The T1D Exchange clinic registry. In: Tamborlane WV BR, Miller KM, DuBose SN, Hall CA, Network TDEC, eds. Vol 97. J Clin Endocrinol Metab 2012; 4383-4389.
5. Battelino T, Phillip M, Bratina N, et al. Effect of continuous glucose monitoring on hypoglycemia in type 1 diabetes. Diabetes Care 2011; 34:795-800.
6. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensoraugmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010; 363:311-320.
7. Tamborlane W, Beck R, BoDe B, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008; 359:1464-1476.
8. SteilGM, Rebrin K, Darwin C, et al. Feasibility of automating insulin Delivery for the treatment of type 1 diabetes. Diabetes 2006; 55:3344-3350. (Pubitemid 44923591)
9. Weinzimer S, Steil G, Swan K, et al. Fully automated clo sed-loop insulin Delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2008; 31:934-939.
10. Hovorka R, Allen J, Elleri D, et al. Manual closed-loop insulin Delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 2010; 375:743-751.
11. Atlas E, Nimri R, Miller S, et al. MD-logic artificial pancreas system: a pilot study in adults with type 1 diabetes. Diabetes Care 2010; 33:1072-1076.
12. Miller S, Nimri R, Atlas E, et al. Automatic learning algorithm for the MD-logic artificial pancreas system. Diabetes Technol Ther 2011; 13:983-990.
13. Luijf YM, DeVries JH, ZwinDerman K, et al. Day and night closed-loop control in adults with type 1 diabete s: a comparison of two closed-loop algorithms driving continuous subcutaneous insulin infusion versus patient self-management. Diabetes Care 2013; 36:3882-3887.
14. El-Khatib F, Russell S, Nathan D, et al. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med 2010; 2:27-27.
15. Breton M, Farret A, Bruttomes so D, et al. Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes 2012; 61:2230-2237.
16. Dauber A, Corcia L, Safer J, et al. Closed-loop insulin therapy improves glycemic control in children aged years: a randomized controlled trial. Diabetes Care 2013; 36:222-227
17. Nimri R, Atlas E, Ajzensztejn M, et al. Feasibili ty study of automated overnight closed-loop glucose control unDer MD-logic artificial pancreas in patients with type 1 diabetes: the DREAM Project. Diabetes Technol Ther 2012; 14:728-735.
18. Nimri R,Danne T.Kordonouri O,et al, The ' Glucositter' overnight automated closed loop system for type 1 diabetes: a randomized crossover trial,Pediatric Diabetes,2013,14,196-202.
19. Russell SJ, El-Khatib FH, Nathan DM, et al. Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diabetes Care 2012; 35:2148-2155.
20. Buckingham BA, Beck RW, Ruedy KJ, et al . The effects of inpatient hybrid closed-loop therapy initiated within 1 week of type 1 diabetes diagnosis. Diabetes Technol Ther 2013; 15:401-408.
21. Murphy HR, Elleri D, Allen JM, et al. Closed-loop insulin Delivery during pregnancy complicated by type 1 diabetes. Diabetes Care 2011; 34: 406-411.
22. Kumareswaran K, Thabit H, Leelarathna L, et al. Feasibility of closed-loop ins ulin Delivery in type 2 diabetes: a randomised controlled study. Diabetes Care 2014; 37:1198-1203.
23. Leelarathna L, English SW, Thabit H, et al. Accuracy of subcutaneous continuous glucose mon itoring in critically ill adults: improved sensor performance with enhanced calibrations. Diabetes Technol Ther 2014; 16:97-101.
24. Pickup JC. Semi-closed-loop insulin Delivery systems: early experience with lowglucose insulin suspend pumps. Diabetes Technol Ther 2011; 13:695-698.
25. Ly TT, Nicholas JA, Retterath A, et al. Effect of sensor-augmented insulin pump therapy and automated insulin sus pension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA 2013; 310:1240-1247.
26. Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013; 369:224-232.
27. Buckingham B, Cobry E, Clinton P, et al. Preventing hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Technol Ther 2009; 11:93-97.
28. Buckingham BA, Cameron F, Calhoun P, et al. Outpatient safety assessment of an in-home predictive low-glucose suspend system with type 1 diabetes subjects at elevated risk of nocturnal hypoglycemia. Diabetes Techno l Ther 2013; 15:622-627.
29. Danne T, Tsioli C, Kordonouri O, et al. The PILGRIM Study: in silico moDeling of a predictive low glucose management system and feasibility in youth with type 1 diabetes during exercise. Diabetes Technol Ther 2014; 15:27-33.
30. Buckingham B, Block J, Burdick J, et al. Response to nocturnal alarms using a real-time glucose sensor. Diabetes Technol Ther 2005; 7:440-447. (Pubitemid 40847806)
31. King P, Kong MF, Parkin H, et al. Well being, cerebral function, and physical fatigue after nocturnal hypoglycemia in IDDM. Diabetes Care 1998; 21:341-345. (Pubitemid 28101066)
32. Maahs DM, Chase HP, Westfall E, et al. The effects of lowering nighttime and breakfast glucose levels with sensor-augmented pump therapy on hemoglobin A1c levels in type 1 diabetes. Diabetes Technol Ther 2014 ; 16:284-291.
33. Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 2013; 368:824-833.
34. Nimri R, Muller I, Atlas E, et al. Night glucose control with MD-Logic artificial pancreas in home setting: a single blind, randomized crossover trial-interim analysis. Pediatr Diabetes 2014; 15:91-99.
35. Danne T et al. An overnight automated closed-loop, MD-Logic system at patient's home presented at the 7th International Conference on AdVanced Technologies & Treatments for Diabetes 2014; Vienna, Austria.
36. Muller I et al. MD-Logic overnight control for long-term home use in patients with type 1 diabetes: randomized crossover trial presented at the 7th International Conference on AdVanced Technologies & Treatments for Diabetes 2014; Vienna, Austria.
37. Hovorka R, et al. Overnight closed-loop insulin Delivery in young people with type 1 diabertes: a free-living randomized clinical trail. Diabetes Care 2014; 37:1204-1211.
38. O'Grady MJ, Retterath AJ, Keenan DB, et al. The use of an automated, portable glucose control system for overnight glucose control in adolescents and young adults with type 1 diabetes. Diabetes Care 2012; 35:2182-2187.
39. Clarke W,AnDerson S,Breton M,et al,Closed-loop artificial pancreas using subcutaneous glucose sensing and insulin Delivery and a moDel predictive control algorithm: the Virginia expe rience, J Diabetes Sci Technol, 2009,3,1031-1103.
40. Kovatchev BP, Renard E, Cobelli C, et al. Feasibility of outpatient fully integrated closed-loop control: first studies of wearable artificia l pancreas. Diabetes Care 2013; 36:1851-1858.
41. Damiano Ed et al. Becon Hill Study presented at the 7th International Conference on AdVanced Technologies & Treatments for Diabetes 2014; Vienna, Austria.
42. Elleri D, Allen JM, Kumareswaran K, et al. Closed-loop basal insulin Delivery over 36 h in adolescents with type 1 diabetes: randomized clinical trial. Diabetes Care 2013; 36:838-844.
43. Van Bon AC, Luijf YM, Koebrugge R, et al. Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home unDer free-living conditions for 48 h. Diabetes Technol Ther 2014; 16:131-136.
44. Atlas E. MD-Logic Closed-loop control with two sensors at a diabetes camp. Paper presented at: 6th International Conference on AdVanced Technologies & Treatments for Diabetes.2013; Paris, France.
45. Basu A, Dube S, Slama M, et al. Time lag of glucose from intravascular to interstitial compartment in humans. Diabetes 2013; 62:4083-4087.